Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In fact, there are several evidence-based weight loss treatments available right now, many with strong clinical data and real-world use behind them
According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common) Decreased appetite (very common) Vomiting (common, affecting up to 1 in 10 people) Constipation (common) Abdominal pain (common) Dyspepsia (common) Cholelithiasis (common) Headache (common) These gastrointestinal effects typically occur during the initial weeks of treatment or following dose escalation, and often diminish over time as the body adjusts to the medication
The isoelectric point (pI) was calculated at 5.35 for nGLP1-DARPin and mGLP1-DARPin-1 and 5.01 for mGLP1-DARPin-2, indicating the dominance of amino acids with negative charges
In addition to chronic weight management, orforglipron is being studied as a potential treatment for Type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, and stress urinary incontinence
